MedTrace Logo

Prognostic Value of CD4/CD8 Ratio in Patients with Nasopharyngeal Carcinoma

NCT06762470 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 325

Last updated 2025-01-09

No results posted yet for this study

Summary

In our previous retrospective study, we identified circulating immune cell counts and the CD4/CD8 ratio as significant prognostic markers in nasopharyngeal carcinoma. Building on these findings, this study aims to conduct a multi-center prospective observational study to evaluate the prognostic value of the circulating lymphocyte CD4/CD8 ratio in nasopharyngeal carcinoma patients prior to treatment.

Conditions

  • Histopathological Diagnosis of Nasopharyngeal Carcinoma
  • Patients with Nasopharyngeal Carcinoma Without Distant Metastases After AJCC/UACC 8th Edition

Sponsors & Collaborators

  • Jiangxi Provincial Cancer Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2028-12-31
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06762470 on ClinicalTrials.gov